![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, October 29, 2011 12:18:49 PM
Reasonable to make inferences: "On the other hand if you "choose" cell host line based on certain parameters(to prove sameness) you will likely infringe on MNTA's patent at least for NEXT 20 years-2031(This patent is fresh out of the oven.filed in October 2011) "
It is a hypothetical, but far too tenuated to make any inferences that one could rely on. MNTA would need to become a litigation machine, like RMBS, worse...and this is far from clear, although a possible theory as to MNTA's future valuation.
I somehow doubt though that MNTA will be able to gate the FoB market like this into 2030...their strategy is to create biogenerics where everyone else creates biosimilars. Much better strategy if you ask me, much more reasonable and practical business plan than trying to patent the entire field against the likes of Novartis, Teva, Amgen, et al. That is a losing strategy in the end, much like the automatic windshield wiper.
Tinker
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM